Navigation Links
New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event
Date:5/24/2012

SAN ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An advisory board of industry leaders at the 2012 Texas Life Science Venture Forum in Houston, Texas namedTransCU O2®, a cutting-edge therapy for chronic wounds, one of ten Most Promising Life Science Technologies.  Over 60 companies were invited to present their research and innovations to hundreds of early-stage investors, venture capitalists, and industry leaders.

This award represents another important achievement for Electrochemical Oxygen Concepts (EO2), the maker of the TransCU O2®.  The company has also recently received recognition by the Department of Veterans Affairs.  EO2 CEO Michael Wells says he and his team are honored by the accolades.

"Patients suffering from chronic wounds and their physicians have long been in need of a better therapy to treat their condition," said Wells. "This award from the Texas Life Science Venture Forum further confirms that TransCU O2® is a ground breaking therapy with the ability to improve the health and lives of patients who suffer with difficult-to heal wounds."

The TransCU O2® is a simple-to-use and easy-to-administer therapy that provides a continuous supply of low-dose pure oxygen to treat a variety of wound types such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.  Oxygen-based therapies have been proven effective in treating chronic wounds but current therapeutic approaches do not allow for 24-hour a day wound treatment.  The TransCU O2® device is lightweight and fully portable.  Its advanced technology allows for the constant monitoring and automatic flow adjustments necessary for the delivery of optimum therapeutic oxygen flow to the wound site.

The Texas Life Science Venture Forum is a joint effort between the Rice Alliance of Technology and Entrepreneurship, BioHouston, and the Texas Healthcare and BioScience Institute and part of the three-day Texas Life Science Conference.  The conference is the most comprehensive showcase of cutting-edge research and innovative entrepreneurs in the state.  Hundreds of investors, entrepreneurs, successful business people and industry leaders attended to learn about, evaluate and network with the presenting companies.

About Electrochemical Oxygen Concepts (EO2™ Concepts):
EO2™ Concepts is a privately held advanced wound care technology company and the developer of an innovative FDA cleared Class III medical device that provides therapy to difficult-to-heal wounds.  The TransCu O2® is an electrochemical low-dose tissue oxygenation and wound monitoring system designed for use with advanced wound dressings as an adjunctive therapy to treat oxygen compromised wounds.  TransCU O2® is a registered trade mark of Electrochemical Oxygen Concepts.  For more information, please visit www.eo2concepts.com.  

Media Contact: Megan Augustine Megan Augustine, 210-296-9520, mg.augustine@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Electrochemical Oxygen Concepts
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
3. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
4. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
5. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
6. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
9. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
10. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
11. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... 28, 2017 , ... Rob Lowe is a popular actor that has been ... to an educational purpose as the host of the “Informed” series. The program focuses ... recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is an ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying ... will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive ... executive resume and wondering if it’s as ready as you are for a new ...
Breaking Medicine News(10 mins):